The introduction of immune checkpoint inhibitors Keytruda (Merck & Co.), Opdivo ± Yervoy (Bristol Myers Squibb), and Tecentriq (Roche / Genentech; United States only), as well as BRAF/MEK …
DRG expects the next ten years to be transitional for patients with hemophilia A, with and without inhibitors, as both the number of therapy options and size of the hemophilia market increase. With…
The psoriasis therapy market has become increasingly lucrative owing to the growing use of targeted agents. The dominance of the tumor necrosis factor (TNF)-alpha inhibitors and interleukin (IL)-12…
Breast cancer is the most commonly diagnosed cancer in women in China. The disease has been managed primarily through chemotherapy in China, but several novel, premium-priced targeted therapies—…
China has the highest incidence of gastroesophageal cancer globally, and therapeutic options are limited. Only five targeted agents are approved for treatment—trastuzumab (Roche’s Herceptin,…
Chemotherapy remains the dominant cornerstone of colorectal cancer treatment and is prescribed with angiogenesis or EGFR inhibitors in the metastatic setting. Patient biomarker status (e.g., BRAF,…
The wet age-related macular degeneration (AMD) therapy market has long been dominated by three VEGF inhibitors—Roche / Genentech / Chugai’s Avastin, Roche / Genentech / Novartis’s Lucentis,…
Chemotherapy and hormonal therapy have been the mainstay treatments of advanced endometrial carcinoma, but treatment is becoming more directed, as a result of tumor analysis. Immune checkpoint…
Clarivate Epidemiology’s coverage of hepatitis c virus (HCV) comprises epidemiological estimates of key patient populations in 45 countries. We report both the incidence and prevalence of HCV for…
DRG Epidemiology's coverage of hepatitis C comprises epidemiological estimates of key patient populations across 45 countries worldwide. We report both the incidence and prevalence of hepatitis…
Bladder cancer is the eighth most commonly diagnosed cancer in China. The bladder cancer therapy market is set to enter a competitive and dynamic period of rapid growth, fueled by one of the most…
Clarivate Epidemiology’s coverage of hepatitis c virus (HCV) comprises epidemiological estimates of key patient populations in 45 countries. We report both the incidence and prevalence of HCV for…
DRG Epidemiology’s coverage of hepatitis C virus (HCV) comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report both the incidence and prevalence of HCV…
DRG Epidemiology’s coverage of hepatitis C virus (HCV) comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report both the incidence and prevalence of HCV…
Clarivate Epidemiology’s coverage of hepatitis Cc virus (HCV) comprises epidemiological estimates of key patient populations inacross 45 countries worldwide. We report both the incidence and…
